Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daihan Pharmaceutical Co., Ltd. (023910:KRX), powered by AI.
Daihan Pharmaceutical Co., Ltd. is currently trading at ₩26,600. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daihan Pharmaceutical Co., Ltd. on Alpha Lenz.
Daihan Pharmaceutical Co., Ltd.'s P/E ratio is 5.8.
“Daihan Pharmaceutical Co., Ltd. trades at a P/E of 5.8 (undervalued) with solid ROE of 9.6%.”
Ask for details →Daihan Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry focused on the development, manufacturing, and marketing of an extensive range of medicinal products. The company specializes in producing over-the-counter drugs, prescription medicines, and health supplements, playing a crucial role in addressing various health conditions and improving patient outcomes. Daihan Pharmaceutical is known for its innovative approach to research and development, ensuring a steady pipeline of new and effective treatments. The company serves a widespread market, contributing significantly to the healthcare sector's advancement by catering to hospitals, clinics, and pharmacies. With its headquarters located in South Korea, Daihan Pharmaceutical has established itself as a vital entity in the Asian pharmaceutical landscape. Its strategic partnerships and rigorous adherence to quality control enhance its market significance, ensuring the delivery of high-standard products that meet global health safety guidelines.
“Daihan Pharmaceutical Co., Ltd. trades at a P/E of 5.8 (undervalued) with solid ROE of 9.6%.”
Ask for details →Daihan Pharmaceutical Co., Ltd. (ticker: 023910) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $159.6B.
The current price is ₩26,600 with a P/E ratio of 5.77x and P/B of 0.53x.
ROE is 9.60% and operating margin is 14.95%. Annual revenue is $208.6B.